STIM VS OCEA Stock Comparison

Performance

STIM
10/100

STIM returned -72.04% in the last 12 months. Based on SPY's performance of -13.39%, its performance is below average giving it a score of 10 of 100.

OCEA
10/100

OCEA returned -87.55% in the last 12 months. Based on SPY's performance of -12.52%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

STIM
90/100

5 analysts offer 12-month price targets for STIM. Together, they have an average target of 8, the most optimistic target put STIM at 8 within 12-months and the most pessimistic has STIM at 8.

OCEA

"Analyst Price Targets" not found for OCEA

Sentiment

STIM
74/100

STIM had a bullish sentiment score of 74.22% across Twitter and StockTwits over the last 12 months. It had an average of 3.11 posts, 0.22 comments, and 0.44 likes per day.

OCEA

"Sentiment" not found for OCEA

Technicals

STIM
64/100

STIM receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

OCEA

"Technicals" not found for OCEA

Earnings

STIM
24/100

STIM has missed earnings 4 times in the last 20 quarters.

OCEA
41/100

OCEA has missed earnings 2 times in the last 20 quarters.

Profit

STIM
10/100

Out of the last 20 quarters, STIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

OCEA
10/100

Out of the last 11 quarters, OCEA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

STIM
33/100

STIM has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

OCEA
60/100

OCEA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Neuronetics, Inc. Common Stock Summary

Nasdaq / STIM

Healthcare

Medical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Ocean Biomedical, Inc. Common Stock Summary

Nasdaq / OCEA

Healthcare

Biotechnology

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Power up your portfolio